Stereotaxis, Inc. (STXS)

Market Cap	201.22M
Revenue (ttm)	26.77M
Net Income (ttm)	-22.06M
Shares Out	82.13M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,286
Open	2.580
Previous Close	2.580
Day's Range	2.450 - 2.600
52-Week Range	1.330 - 3.290
Beta	1.34
Analysts	Strong Buy
Price Target	4.50 (+83.67%)
Earnings Date	May 7, 2024

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 12, 2004
• Employees: 122
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: STXS

Financial Performance

In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 83.67% from the latest price.

Price Target

$4.5

(83.67% upside)

Analyst Consensus: Strong Buy